By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation) 

3805 Old Easton Road
Doylestown, PA 18902

8900 Glenlyon Parkway

Burnaby,  British Columbia,  V5J 5J8  Canada
Phone: 604-419-3200 Fax: 604-419-3201


Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.


October 6, 2005


CEO: Mark Murray

CMO (Medical): Mark Kowalski

CFO: Bruce Cousins

CSO (Scientific): Michael Sofia

CTO: Peter Lutwyche


Please click here for Arbutus job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Arbutus Biopharma
Employees: <500 Employees
Symbol: ABUS

Company News
A Look At The Beef Between Arbutus Biopharma (ABUS) And Biotech Unicorn Moderna 5/17/2017 5:44:02 AM
Arbutus Biopharma (ABUS) Presents HBV Drug Combination Studies At ICAR 5/10/2017 8:09:06 AM
Arbutus Biopharma (ABUS) Announces Corporate Update And First Quarter 2017 Financial Results 5/5/2017 11:13:10 AM
Arbutus Biopharma (ABUS) Announces Conference Call To Provide A Corporate Update And First Quarter 2017 Financial Results 5/2/2017 8:11:53 AM
Arbutus Biopharma (ABUS) Announces ARB-1467 Data Presentation At EASL4/24/2017 8:19:30 AM
Arbutus Biopharma (ABUS) Injunction Survives Attempted Appeal By Acuitas Therapeutics 4/13/2017 9:40:28 AM
Arbutus Biopharma (ABUS) Announces Appointment Of Daniel Burgess To Board Of Directors 3/24/2017 7:45:01 AM
Arbutus Biopharma (ABUS) Announces Year-End 2016 Financial Results 3/21/2017 9:02:07 AM
Alexion (ALXN), Arbutus Biopharma (ABUS) Ink $80 Million Rare Disease mRNA Deal 3/17/2017 8:13:39 AM
Arbutus Biopharma (ABUS) Is Granted A Pre-Trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 2/8/2017 7:44:15 AM